The DOI matches its Crossref record; 165 of the 165 references it cites were found in a registry or an index.
Advances in mRNA Vaccines for Infectious Diseases
Open accessAbstract
During the last two decades, there has been broad interest in RNA-based technologies for the development of prophylactic and therapeutic vaccines. Preclinical and clinical trials have shown that mRNA vaccines provide a safe and long-lasting immune response in animal models and humans. In this review, we summarize current research progress on mRNA vaccines, which have the potential to be quick-manufactured and to become powerful tools against infectious disease and we highlight the bright future of their design and applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs
Kozak, M. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.20.8125 · Cited by 5,087
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · cited 4×
“Due to the dramatic development of RNA-based vaccine studies and applications, a plethora of mRNA vaccines have entered into clinical trial (19).”
BackgroundMethodInfluentialDirect Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · cited 1×
“Stability and translation of mRNA is crucial for a successful RNA vaccine (32, 33).”
BackgroundSignaling to NF-κB by Toll-like receptors
Kawai, T., & Akira, S. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.09.002 · Cited by 2,388
Toxicity of cationic lipids and cationic polymers in gene delivery
Lv, H., Zhang, S., Wang, B., Cui, S., & Yan, J. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.014 · Cited by 2,286
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
mRNA stability in mammalian cells
Ross, J. (1995) · Microbiological Reviews · doi:10.1128/mr.59.3.423-450.1995 · Cited by 1,411
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
DNA vaccines: ready for prime time?
Kutzler, M. A., & Weiner, D. B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2432 · Cited by 1,077 · cited 1×
“Although promising and with shown safety, well-tolerability and immunogenicity, DNA vaccines were characterized by suboptimal potency in early clinical trials (11).”
BackgroundmRNA is an endogenous ligand for toll-like receptor 3
Karikó, K., Ni, H., Capodici, J., Lamphier, M., & Weissman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310175200 · Cited by 1,062
Hershberg, R., & Petrov, D. A. (2008) · Annual Review of Genetics · doi:10.1146/annurev.genet.42.110807.091442 · Cited by 1,061
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
mRNA capping: biological functions and applications
Ramanathan, A., Robb, G. B., & Chan, S.-H. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 898
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency.
Gallie, D. R. (1991) · Genes & Development · doi:10.1101/gad.5.11.2108 · Cited by 868
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
Goubau, D., Deddouche, S., & Reis e Sousa, C. (2013) · Immunity · doi:10.1016/j.immuni.2013.05.007 · Cited by 843
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 741
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy
Oberli, M. A., Reichmuth, A. M., Dorkin, J. R., Mitchell, M. J., Fenton, O. S., Jaklenec, A., Anderson, D. G., Langer, R., & Blankschtein, D. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b03329 · Cited by 719
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq347 · Cited by 682
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Holtkamp, S., Kreiter, S., Selmi, A., Simon, P., Koslowski, M., Huber, C., Türeci, O., & Sahin, U. (2006) · Blood · doi:10.1182/blood-2006-04-015024 · Cited by 625
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Developing mRNA-vaccine technologies
Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K.-J. (2012) · RNA Biology · doi:10.4161/rna.22269 · Cited by 622
OPTIMIZER: a web server for optimizing the codon usage of DNA sequences
Puigbo, P., Guzman, E., Romeu, A., & Garcia-Vallve, S. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm219 · Cited by 603
RIG-I detects viral genomic RNA during negative-strand RNA virus infection
Rehwinkel, J., Tan, C. P., Goubau, D., Schulz, O., Pichlmair, A., Bier, K., Robb, N., Vreede, F., Barclay, W., Fodor, E., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.020 · Cited by 585
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Zost, S. J., Parkhouse, K., Gumina, M. E., Kim, K., Diaz Perez, S., Wilson, P. C., Treanor, J. J., Sant, A. J., Cobey, S., & Hensley, S. E. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712377114 · Cited by 563 · cited 1×
“In contrast, the process of mRNA vaccine production is egg-free, and mRNA-encoded proteins are properly folded and glycosylated in host cells after vaccine administration, thus avoiding the risk of producing incorrect antigens (67, 68).”
BackgroundAntiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates
Goubau, D., Schlee, M., Deddouche, S., Pruijssers, A. J., Zillinger, T., Goldeck, M., Schuberth, C., Van der Veen, A. G., Fujimura, T., Rehwinkel, J., et al. (2014) · Nature · doi:10.1038/nature13590 · Cited by 557
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 556
Pardi, N., Hogan, M. J., Naradikian, M. S., Parkhouse, K., Cain, D. W., Jones, L., Moody, M. A., Verkerke, H. P., Myles, A., Willis, E., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171450 · Cited by 530
Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530
Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501
Regulation of antiviral T cell responses by type I interferons
Crouse, J., Kalinke, U., & Oxenius, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3806 · Cited by 479
High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells
Kudla, G., Lipinski, L., Caffin, F., Helwak, A., & Zylicz, M. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040180 · Cited by 476
Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA
Martinon, F., Krishnan, S., Lenzen, G., Magné, R., Gomard, E., Guillet, J., Lévy, J., & Meulien, P. (1993) · European Journal of Immunology · doi:10.1002/eji.1830230749 · Cited by 473
The Yin and Yang of type I interferon activity in bacterial infection
Decker, T., Müller, M., & Stockinger, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1684 · Cited by 468
Petsch, B., Schnee, M., Vogel, A. B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.-J., Stitz, L., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2436 · Cited by 464
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
Materials for non-viral intracellular delivery of messenger RNA therapeutics
Kauffman, K. J., Webber, M. J., & Anderson, D. G. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.032 · Cited by 395
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
Guan, S., & Rosenecker, J. (2017) · Gene Therapy · doi:10.1038/gt.2017.5 · Cited by 389
Plasmacytoid dendritic cells sense skin injury and promote wound healing through type I interferons
Gregorio, J., Meller, S., Conrad, C., Di Nardo, A., Homey, B., Lauerma, A., Arai, N., Gallo, R. L., DiGiovanni, J., & Gilliet, M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20101102 · Cited by 367
Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352 · cited 1×
“Interestingly, a recent publication by Pardi and colleagues showed that the adnimistration of mRNA encoding the light and heavy chains of a broadly neutralizing anti-HIV antibody encapsulated in lipid nanoparticles (LNPs) protected humanized mice from intravenous HIV challenge (79).”
BackgroundA Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338
Resident and “Inflammatory” Dendritic Cells in Human Skin
Zaba, L. C., Krueger, J. G., & Lowes, M. A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.225 · Cited by 319
Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0699 · Cited by 309
Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., et al. (2015) · Journal for Immunotherapy of Cancer · doi:10.1186/s40425-015-0068-y · Cited by 287
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0032-6 · Cited by 282
Karikó, K., Muramatsu, H., Keller, J. M., & Weissman, D. (2012) · Molecular Therapy · doi:10.1038/mt.2012.7 · Cited by 282
Immunotherapy Against HPV16/18 Generates Potent T H 1 and Cytotoxic Cellular Immune Responses
Bagarazzi, M. L., Yan, J., Morrow, M. P., Shen, X., Parker, R. L., Lee, J. C., Giffear, M., Pankhong, P., Khan, A. S., Broderick, K. E., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004414 · Cited by 282
Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S. J., Mui, B. L., Tam, Y. K., Karikó, K., Barbosa, C. J., Madden, T. D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05482-0 · Cited by 281
Caskey, M., Lefebvre, F., Filali-Mouhim, A., Cameron, M. J., Goulet, J.-P., Haddad, E. K., Breton, G., Trumpfheller, C., Pollak, S., Shimeliovich, I., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20111171 · Cited by 271
TLR signaling in B-cell development and activation
Hua, Z., & Hou, B. (2013) · Cellular & Molecular Immunology · doi:10.1038/cmi.2012.61 · Cited by 269
Sheehan, K. C. F., Lai, K. S., Dunn, G. P., Bruce, A. T., Diamond, M. S., Heutel, J. D., Dungo-Arthur, C., Carrero, J. A., White, J. M., Hertzog, P. J., et al. (2006) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2006.26.804 · Cited by 260
MDA5 Detects the Double-Stranded RNA Replicative Form in Picornavirus-Infected Cells
Feng, Q., Hato, S. V., Langereis, M. A., Zoll, J., Virgen-Slane, R., Peisley, A., Hur, S., Semler, B. L., van Rij, R. P., & van Kuppeveld, F. J. M. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.005 · Cited by 252
Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.202 · Cited by 248
McKinlay, C. J., Benner, N. L., Haabeth, O. A., Waymouth, R. M., & Wender, P. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805358115 · Cited by 238
Mechanism of action of mRNA-based vaccines
Iavarone, C., O’hagan, D. T., Yu, D., Delahaye, N. F., & Ulmer, J. B. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1355245 · Cited by 234 · cited 1×
“mRNA vaccines expressing antigen of infectious pathogen induce both strong and potent T cell and humoral immune responses (8, 16, 19).”
BackgroundSchnee, M., Vogel, A. B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., & Stitz, L. (2016) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0004746 · Cited by 230
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228 · cited 1×
“Stability and translation of mRNA is crucial for a successful RNA vaccine (32, 33).”
BackgroundA structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine
Wu, N. C., Zost, S. J., Thompson, A. J., Oyen, D., Nycholat, C. M., McBride, R., Paulson, J. C., Hensley, S. E., & Wilson, I. A. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006682 · Cited by 227
Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice
Hekele, A., Bertholet, S., Archer, J., Gibson, D. G., Palladino, G., Brito, L. A., Otten, G. R., Brazzoli, M., Buccato, S., Bonci, A., et al. (2013) · Emerging Microbes & Infections · doi:10.1038/emi.2013.54 · Cited by 226
Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals
Kreiter, S., Selmi, A., Diken, M., Sebastian, M., Osterloh, P., Schild, H., Huber, C., Türeci, O., & Sahin, U. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.309 · Cited by 225
A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines
Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25181 · Cited by 223
Master sensors of pathogenic RNA – RIG-I like receptors
Schlee, M. (2013) · Immunobiology · doi:10.1016/j.imbio.2013.06.007 · Cited by 217
Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy
Van Lint, S., Goyvaerts, C., Maenhout, S., Goethals, L., Disy, A., Benteyn, D., Pen, J., Bonehill, A., Heirman, C., Breckpot, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2957 · Cited by 210
Pepini, T., Pulichino, A.-M., Carsillo, T., Carlson, A. L., Sari-Sarraf, F., Ramsauer, K., Debasitis, J. C., Maruggi, G., Otten, G. R., Geall, A. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601877 · Cited by 208
Probst, J., Weide, B., Scheel, B., Pichler, B. J., Hoerr, I., Rammensee, H.-G., & Pascolo, S. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302964 · Cited by 206 · cited 1×
“In the process of translation, mRNA purity is critical to determine its stability and protein yield (34).”
BackgroundIn Vitro Transcription of Long RNA Containing Modified Nucleosides
Pardi, N., Muramatsu, H., Weissman, D., & Karikó, K. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-260-5_2 · Cited by 204
Li, M., Zhao, M., Fu, Y., Li, Y., Gong, T., Zhang, Z., & Sun, X. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.043 · Cited by 201
Biomaterials for vaccine-based cancer immunotherapy
Zhang, R., Billingsley, M. M., & Mitchell, M. J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.008 · Cited by 200
Sedic, M., Senn, J. J., Lynn, A., Laska, M., Smith, M., Platz, S. J., Bolen, J., Hoge, S., Bulychev, A., Jacquinet, E., et al. (2018) · Veterinary Pathology · doi:10.1177/0300985817738095 · Cited by 195
Self-replicating Semliki Forest virus RNA as recombinant vaccine
Zhou, X., Berglund, P., Rhodes, G., Parker, S. E., Jondal, M., & Liljeström, P. (1994) · Vaccine · doi:10.1016/0264-410x(94)90074-4 · Cited by 193
Silencing or Stimulation? siRNA Delivery and the Immune System
Whitehead, K. A., Dahlman, J. E., Langer, R. S., & Anderson, D. G. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114133 · Cited by 191
Coolen, A.-L., Lacroix, C., Mercier-Gouy, P., Delaune, E., Monge, C., Exposito, J.-Y., & Verrier, B. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.12.019 · Cited by 191
Wang, Y., Su, H.-H., Yang, Y., Hu, Y., Zhang, L., Blancafort, P., & Huang, L. (2013) · Molecular Therapy · doi:10.1038/mt.2012.250 · Cited by 183
RNA: The new revolution in nucleic acid vaccines
Geall, A. J., Mandl, C. W., & Ulmer, J. B. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.05.001 · Cited by 183
Bogers, W. M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E. J., Davis, D., Ulmer, J. B., Brito, L. A., Cu, Y., Banerjee, K., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu522 · Cited by 181
HPLC purification of in vitro transcribed long RNA
Weissman, D., Pardi, N., Muramatsu, H., & Karikó, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_3 · Cited by 180
Meyer, M., Huang, E., Yuzhakov, O., Ramanathan, P., Ciaramella, G., & Bukreyev, A. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix592 · Cited by 178
Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines
Deering, R. P., Kommareddy, S., Ulmer, J. B., Brito, L. A., & Geall, A. J. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.901308 · Cited by 176
Fleeton, M. N., Chen, M., Berglund, P., Rhodes, G., Parker, S. E., Murphy, M., Atkins, G. J., & Liljeström, P. (2001) · The Journal of Infectious Diseases · doi:10.1086/319857 · Cited by 157
Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L. M., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01786-15 · Cited by 154
Self-replicating alphavirus RNA vaccines
Ljungberg, K., & Liljeström, P. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2015.965690 · Cited by 149
Maruggi, G., Chiarot, E., Giovani, C., Buccato, S., Bonacci, S., Frigimelica, E., Margarit, I., Geall, A., Bensi, G., & Maione, D. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.11.040 · Cited by 149
Self-citationHaabeth, O. A. W., Blake, T. R., McKinlay, C. J., Waymouth, R. M., Wender, P. A., & Levy, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810002115 · Cited by 148
Lint, S. V., Renmans, D., Broos, K., Goethals, L., Maenhout, S. K., Benteyn, D., Goyvaerts, C., Four, S. D., der Jeught, K. V., Bialkowski, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0163 · Cited by 139
Kallen, K., & Theß, A. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613508729 · Cited by 137
Design of Polymeric Gene Carriers for Effective Intracellular Delivery
Lai, W., & Wong, W. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.02.006 · Cited by 137
Magini, D., Giovani, C., Mangiavacchi, S., Maccari, S., Cecchi, R., Ulmer, J. B., Gregorio, E. D., Geall, A. J., Brazzoli, M., & Bertholet, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161193 · Cited by 134
Lindgren, G., Ols, S., Liang, F., Thompson, E. A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K. J., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01539 · Cited by 132
Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA
Zhao, M., Li, M., Zhang, Z., Gong, T., & Sun, X. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1038856 · Cited by 132
Nucleoside modified mRNA vaccines for infectious diseases
Pardi, N., & Weissman, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_6 · Cited by 129
Liu, G., Park, H.-S., Pyo, H., Liu, Q., & Zhou, Y. (2015) · Journal of Virology · doi:10.1128/jvi.00232-15 · Cited by 128
A Sendai Virus-Derived RNA Agonist of RIG-I as a Virus Vaccine Adjuvant
Martínez‐Gil, L., Goff, P. H., Hai, R., García‐Sastre, A., Shaw, M. L., & Palese, P. (2012) · Journal of Virology · doi:10.1128/jvi.02338-12 · Cited by 127
Routy, J., Boulassel, M., Yassine‐Diab, B., Nicolette, C. A., Healey, D. G., Jain, R., Landry, C., Yegorov, O., Tcherepanova, I. Y., Monesmith, T., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.09.009 · Cited by 124
An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections
VanBlargan, L. A., Himansu, S., Foreman, B. M., Ebel, G. D., Pierson, T. C., & Diamond, M. S. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.082 · Cited by 123 · cited 1×
“This mRNA vaccine induced robust humoral immune response not only against POWV strains but also against the distantly related Langat virus (71).”
BackgroundAllard, S. D., Keersmaecker, B. D., de Goede, A. L., Verschuren, E. J., Koetsveld, J., Reedijk, M. L., Wylock, C., Bel, A. V. D., Vandeloo, J., Pistoor, F. H. M., et al. (2011) · Clinical Immunology · doi:10.1016/j.clim.2011.10.010 · Cited by 121
Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., Verbeke, R., Lentacker, I., Thielemans, K., & Breckpot, K. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.38 · Cited by 121
Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines
Beuckelaer, A. D., Grooten, J., & Koker, S. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.006 · Cited by 120
Ablasser, A., Poeck, H., Anz, D., Berger, M., Schlee, M., Kim-Hellmuth, S., Bourquin, C., Goutagny, N., Jiang, Z., Fitzgerald, K. A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803001 · Cited by 118
A thermostable messenger RNA based vaccine against rabies
Stitz, L., Vogel, A., Schnee, M., Voss, D., Rauch, S., Mutzke, T., Ketterer, T., Kramps, T., & Petsch, B. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006108 · Cited by 117
Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines
Démoulins, T., Milona, P., Englezou, P. C., Ebensen, T., Schulze, K., Suter, R., Pichon, C., Midoux, P., Guzmán, C. A., Ruggli, N., et al. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.11.001 · Cited by 117
Cuzick, J. M. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30536-3 · Cited by 116
Long-term storage of DNA-free RNA for use in vaccine studies
Jones, K. L., Drane, D., & Gowans, E. J. (2007) · BioTechniques · doi:10.2144/000112593 · Cited by 115
Faurez, F., Dory, D., Moigne, V. L., Gravier, R., & Jestin, A. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.03.040 · Cited by 113
Kowalczyk, A., Doener, F., Zanzinger, K., Noth, J., Baumhof, P., Fotin-Mleczek, M., & Heidenreich, R. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.05.046 · Cited by 101
Johanning, F. W., Conry, R. M., LoBuglio, A. F., Wright, M., Sumerel, L. A., Pike, M. J., & Curiel, D. T. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.9.1495 · Cited by 99
mRNA Delivery System for Targeting Antigen‐Presenting Cells In Vivo
Fornaguera, C., Guerra‐Rebollo, M., Lázaro, M. Á., Castells‐Sala, C., Meca‐Cortés, Ó., Ramos‐Pérez, V., Cascante, A., Rubio, N., Blanco, J., & Borrós, S. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800335 · Cited by 98
Gandhi, R. T., Kwon, D. S., Macklin, E. A., Shopis, J., McLean, A. P., McBrine, N., Flynn, T., Peter, L. E., Sbrolla, A., Kaufmann, D., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000852 · Cited by 97
New Kids on the Block: RNA-Based Influenza Virus Vaccines
Scorza, F. B., & Pardi, N. (2018) · Vaccines · doi:10.3390/vaccines6020020 · Cited by 96
Fiedler, K., Lazzaro, S., Lutz, J., Rauch, S., & Heidenreich, R. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42934-2_5 · Cited by 95
Moyo, N., Vogel, A. B., Buus, S., Erbar, S., Wee, E. G., Sahin, U., & Hanke, T. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.010 · Cited by 94
Replicon RNA Viral Vectors as Vaccines
Lundstrom, K. H. (2016) · Vaccines · doi:10.3390/vaccines4040039 · Cited by 92
Recent innovations in mRNA vaccines
Ulmer, J. B., & Geall, A. J. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.008 · Cited by 91
Aberle, J. H., Aberle, S. W., Kofler, R. M., & Mandl, C. W. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15107-15113.2005 · Cited by 91
Extracellular RNA sensing by pattern recognition receptors
Tatematsu, M., Funami, K., Seya, T., & Matsumoto, M. (2018) · Journal of Innate Immunity · doi:10.1159/000494034 · Cited by 90
DNA and mRNA vaccination against allergies
Scheiblhofer, S., Thalhamer, J., & Weiss, R. (2018) · Pediatric Allergy and Immunology · doi:10.1111/pai.12964 · Cited by 86
Maximizing the Translational Yield of mRNA Therapeutics by Minimizing 5′-UTRs
Trepotec, Z., Aneja, M. K., Geiger, J., Hasenpusch, G., Plank, C., & Rudolph, C. (2019) · Tissue Engineering Part A · doi:10.1089/ten.tea.2017.0485 · Cited by 77
Kunjin Virus Replicon Vaccine Vectors Induce Protective CD8+T-Cell Immunity
Anraku, I., Harvey, T. J., Linedale, R., Gardner, J., Harrich, D., Suhrbier, A., & Khromykh, A. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.8.3791-3799.2002 · Cited by 77
Recognition of mRNA cap structures by viral and cellular proteins
Fechter, P., & Brownlee, G. G. (2005) · Journal of General Virology · doi:10.1099/vir.0.80755-0 · Cited by 75
Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus
Zhou, B., Meliopoulos, V., Wang, W., Lin, X., Stucker, K. M., Halpin, R., Stockwell, T. B., Schultz‐Cherry, S., & Wentworth, D. E. (2016) · Journal of Virology · doi:10.1128/jvi.00163-16 · Cited by 75
McCullough, K. C., Bassi, I., Milona, P., Suter, R., Thomann, L., Englezou, P. C., Démoulins, T., & Ruggli, N. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.24 · Cited by 72
Latest Development on RNA-Based Drugs and Vaccines
Lundstrom, K. H. (2018) · Future Science OA · doi:10.4155/fsoa-2017-0151 · Cited by 72
Zohra, F. T., Chowdhury, E. H., Tada, S., Hoshiba, T., & Akaike, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.059 · Cited by 71
Identification of a Natural Viral RNA Motif That Optimizes Sensing of Viral RNA by RIG-I
Xu, J., Mercado-López, X., Grier, J. T., Kim, W.-K., Chun, L. F., Irvine, E. B., Duany, Y. D. T., Kell, A. M., Hur, S., Gale, M., et al. (2015) · mBio · doi:10.1128/mbio.01265-15 · Cited by 71
Gulck, E. R. A. V., Ponsaerts, P., Heyndrickx, L., Vereecken, K., Moerman, F., Roo, A. D., Colebunders, R., den Bosch, G. V., Bockstaele, D. R. V., Tendeloo, V. F. I. V., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0339 · Cited by 69
ε-Poly-l-Lysine/plasmid DNA nanoplexes for efficient gene delivery in vivo
Mandal, H., Katiyar, S. S., Swami, R., Kushwah, V., Katare, P. B., Meka, A. K., Banerjee, S., Popat, A., & Jain, S. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.03.021 · Cited by 68
Nuffel, A. M. T. V., Benteyn, D., Wilgenhof, S., Corthals, J., Heirman, C., Neyns, B., Thielemans, K., & Bonehill, A. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1176-2 · Cited by 66
Cellular and Humoral Immunity Protect against Vaginal Zika Virus Infection in Mice
Scott, J. M., Lebratti, T. J., Richner, J. M., Jiang, X., Fernández, E., Zhao, H., Fremont, D. H., Diamond, M., & Shin, H. (2018) · Journal of Virology · doi:10.1128/jvi.00038-18 · Cited by 65
Vaccination With Messenger RNA
Pascolo, S. (2006) · Humana Press eBooks · doi:10.1385/1-59745-168-1:23 · Cited by 64
Tews, B. A., & Meyers, G. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6481-9_2 · Cited by 64
RIG-I-Like Receptors and Type I Interferonopathies
Kato, H., Oh, S.-W., & Fujita, T. (2017) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2016.0095 · Cited by 59
Craenenbroeck, A. H. V., Smits, E., Anguille, S., de Velde, A. V., Stein, B., Braeckman, T., Camp, K. V., Nijs, G., Ieven, M. M., Goossens, H., et al. (2014) · Transplantation · doi:10.1097/tp.0000000000000272 · Cited by 55
Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development
Harvey, T. J., Anraku, I., Linedale, R., Harrich, D., Mackenzie, J. M., Suhrbier, A., & Khromykh, A. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.14.7796-7803.2003 · Cited by 54
mRNA Cancer Vaccines—Messages that Prevail
Grunwitz, C. R., & Kranz, L. M. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_509 · Cited by 54
Scaffold-mediated delivery for non-viral mRNA vaccines
Chen, R., Zhang, H., Yan, J., & Bryers, J. D. (2018) · Gene Therapy · doi:10.1038/s41434-018-0040-9 · Cited by 50
Hollister, K., Chen, Y., Wang, S., Wu, H., Mondal, A., Clegg, N., Lu, S., & Dent, A. L. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28659 · Cited by 44
Pyankov, O. V., Боднев, С. А., Pyankova, O. G., Solodky, V. V., Pyankov, S. A., Setoh, Y. X., Volchkova, V. A., Suhrbier, A., Volchkov, V. E., Agafonov, A. P., et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv019 · Cited by 44
DeFrancesco, L. (2017) · Nature Biotechnology · doi:10.1038/nbt.3812 · Cited by 44
In Vitro Synthesis of Modified mRNA for Induction of Protein Expression in Human Cells
Avci‐Adali, M., Behring, A., Steinle, H., Keller, T., Krajeweski, S., Schlensak, C., & Wendel, H. P. (2014) · Journal of Visualized Experiments · doi:10.3791/51943 · Cited by 41
Lee, H., Bingham, S. E., & Webber, A. N. (1996) · Plant Molecular Biology · doi:10.1007/bf00021794 · Cited by 41
Saxena, S., Sonwane, A., Dahiya, S. S., Patel, C. L., Saini, M., Rai, A., & Gupta, P. K. (2008) · Veterinary Microbiology · doi:10.1016/j.vetmic.2008.10.030 · Cited by 38
Li, J., Arévalo, M. T., Chen, Y., Chen, S., & Zeng, M. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.05.016 · Cited by 38
Self-citationDissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques
Liang, F., Ploquin, A., Hernández, J. D., Fausther‐Bovendo, H., Lindgren, G., Stanley, D. A., Salvador, A., Brenchley, J. M., Koup, R. A., Loré, K., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2015.06.011 · Cited by 36
Khalil, S. M., Tonkin, D. R., Mattocks, M. D., Snead, A. T., Johnston, R. E., & White, L. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.05.053 · Cited by 34
Expression of the human cytomegalovirus pentamer complex for vaccine use in a CHO system
Hofmann, I., Wen, Y., Ciferri, C., Schulze, A., Fühner, V., Leong, M. J., Gerber, A., Gerrein, R., Nandi, A., Lilja, A. E., et al. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25670 · Cited by 34
Ip, P. P., Boerma, A., Regts, J., Meijerhof, T., Wilschut, J., Nijman, H. W., & Daemen, T. (2013) · Molecular Therapy · doi:10.1038/mt.2013.287 · Cited by 32
RNA immunization can protect mice against foot-and-mouth disease virus
Rodríguez‐Pulido, M., Sobrino, F., Borrego, B., & Sáiz, M. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.12.005 · Cited by 22
Huang, Y.-T., Liao, J.-T., Yen, L.-C., Chang, Y.-K., Lin, Y., & Liao, C. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0181-8 · Cited by 22
Blanchard, E. L., Loomis, K. H., Bhosle, S. M., Vanover, D. A., Baumhof, P., Pitard, B., Zurla, C., & Santangelo, P. J. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.002 · Cited by 21
Tattoo Delivery of a Semliki Forest Virus-Based Vaccine Encoding Human Papillomavirus E6 and E7
van de Wall, S., Walczak, M., van Rooij, N., Hoogeboom, B. N., Meijerhof, T., Nijman, H. W., & Daemen, T. (2015) · Vaccines · doi:10.3390/vaccines3020221 · Cited by 18
Oreshkova, N., Cornelissen, L. A. H. M., de Haan, C. A. M., Moormann, R. J. M., & Kortekaas, J. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.07.051 · Cited by 17
Burgess, D. J. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3159 · Cited by 10
Servick, K. (2017) · Science · doi:10.1126/science.355.6324.446 · Cited by 2
Cited by
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593
Ahn, D.-G., Shin, H.-J., Kim, M.-H., Lee, S., Kim, H.-S., Myoung, J., Kim, B.-T., & Kim, S.-J. (2020) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2003.03011 · Cited by 1,001
COVID-19 Vaccine: A comprehensive status report
Kaur, S. P., & Gupta, V. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198114 · Cited by 852
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
The clinical progress of mRNA vaccines and immunotherapies
Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R., & Anderson, D. G. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01294-2 · Cited by 823
Metadata
- Authors
- Zhang, C., Maruggi, G., Shan, H., & Li, J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-03-27
- Volume
- 10
- Pages
- 594-594
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2923214306
- Cited by
- 665
- References
- 165
- FWCI
- 34.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.